Twin A Breech External Cephalic Version Intervention Trial (TWEXIT)
Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Oct 1, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Twin A Breech External Cephalic Version Intervention Trial (TWEXIT) is a study looking at a specific technique called external cephalic version (ECV) for women expecting twins where the first baby (Twin A) is in a breech position, meaning they are positioned feet or bottom down instead of head down. The goal of this trial is to see if this technique can help safely turn the baby into the head-down position before delivery, which may lead to a better outcome for both mother and babies.
To participate in this trial, women need to be over 18 years old and able to give their consent to join. Unfortunately, women under 18, those with certain pregnancy complications like placenta previa (where the placenta covers the cervix), or those with fetal abnormalities cannot take part in the study. For eligible participants, joining the trial means they will receive care and monitoring related to this technique, and they will be contributing valuable information that could help improve care for future pregnancies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Presence of the written consent of the patients.
- • The patients must be over 18 years old .
- • No limit in the ability to consent.
- Exclusion Criteria:
- • Age under 18
- • Limited ability to consent
- • Placenta previa
- • Fetal abnormalities
About Charite University, Berlin, Germany
Charité - Universitätsmedizin Berlin is a leading academic medical center in Germany, renowned for its commitment to excellence in research, education, and patient care. As one of Europe's largest university hospitals, Charité integrates cutting-edge clinical practices with innovative research initiatives, fostering interdisciplinary collaboration across various medical fields. The institution is dedicated to advancing healthcare through rigorous clinical trials, contributing to the development of new therapies and treatment protocols. With a strong emphasis on translational medicine, Charité aims to bridge the gap between scientific discovery and practical application, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berlin Mitte, , Germany
Patients applied
Trial Officials
Larry Hinkson, FRCOG
Principal Investigator
Charité University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials